Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, parallel controlled, single blind trial is designed to evaluate the efficacy and safety of hydromorphone versus morphine for perioperative analgesia in lung tumor ablation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qianfoshan Hospital
• Treatments: Hydromorphone; Morphine

Criteria

Inclusion Criteria:

• Voluntarily attend and sign the informed consent form in person;

• Patients undergoing selective pulmonary tumor ablation;

• The Eastern Collaborative Oncology Group (ECOG) defines an activity status score of 2 or less;

• The estimated survival time is more than 3 months;

• Age 18-80, both sexes.

Exclusion Criteria:

• Severe coagulation dysfunction that cannot be corrected;

• History of severe cardio-cerebrovascular and respiratory diseases;

• Patients allergic to test drugs or contrast media;

• Patients with opioid addiction;

• Patients with cognitive dysfunction;

• Participated in other clinical investigators within three months;

• Investigators or their family members directly involved in the trial;

• Those who are deemed unfit to participate in the study by the investigator.